Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RORA | P35398 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | RORB | Q92753 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010294 | 0.84 | POLB (0.46) | POLBHTTMEN1KMT2ACYP1A2 | |
| SCHEMBL2010464 | 0.83 | MEN1 (0.46) | POLBHTTMEN1KMT2ACYP1A2 | |
| SCHEMBL3033384 | 0.83 | POLB (0.47) | POLBHTTMEN1KMT2ACYP1A2 | |
| SCHEMBL2008980 | 0.82 | KDM4E (0.51) | MEN1KMT2AMAPT | |
| SCHEMBL29152531 | 0.81 | POLB (0.48) | POLBHTTMEN1KMT2ACYP1A2 | |
| SCHEMBL30827426 | 0.77 | HTR4 (0.57) | POLBHTTHTR4 | |
| SCHEMBL961272 | 0.77 | HTR4 (0.57) | POLBHTTHTR4 | |
| Hydrochloric Acid SCHEMBL9020820 | 0.75 | HTR4 (0.56) | POLBHTTHTR4 | |
| SCHEMBL29152467 | 0.75 | NPY5R (0.40) | POLBHTTMEN1KMT2ACYP1A2 | |
| SCHEMBL3336121 | 0.73 | NOTUM (0.39) | POLBNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964727-B2 | N-({1-[(cis-1,4-dihydroxycyclohexyl)methyl]piperidin-4-yl}methyl)-1-isopropyl-5-methyl-2-oxo-1, 2-dihydroquinoline-3-carboxamide ethanedioate; gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome | PFIZER INC. (US) | 2011-06-21 | — | — | US | disclosed |
| EP-1689742-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1689742-B1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | KATO TOMOKI | 2008-10-16 | — | — | US | disclosed |
| EP-1689742-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | Pfizer, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049608-A1 | QUINOLONECARBOXYLIC ACID COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY | PFIZER JAPAN, INC. (JP) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255113-A1 | Quinolonecarboxylic Acid Compounds Having 5-Ht4 Receptor Agonistic Activity | HTR4, HRH4, HRH2 | POLB 3153/4885HTT 2096/4885MEN1 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.